Multiple metastatic clones assessed by an integrative multiomics strategy in clear cell renal carcinoma: a case study

The dynamics of metastatic evolution in clear cell renal cell carcinoma (ccRCC) are complex. We report a case study where tumour heterogeneity resulting from clonal evolution is a frequent feature and could play a role in metastatic dissemination.We used an integrative multiomics strategy combining...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of clinical pathology 2022-06, Vol.75 (6), p.426-430
Hauptverfasser: Dagher, Julien, Brunot, Angelique, Evrard, Bertrand, Kammerer-Jacquet, Solene-Florence, Beaumont, Marion, Cornevin, Laurence, Derquin, Fanny, Verhoest, Gregory, Bensalah, Karim, Lespagnol, Alexandra, Dugay, Frederic, Belaud-Rotureau, Marc-Antoine, Chalmel, Frédéric, Rioux-Leclercq, Nathalie
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The dynamics of metastatic evolution in clear cell renal cell carcinoma (ccRCC) are complex. We report a case study where tumour heterogeneity resulting from clonal evolution is a frequent feature and could play a role in metastatic dissemination.We used an integrative multiomics strategy combining genomic and transcriptomic data to classify fourteen specimens from spatially different areas of a kidney tumour and three non-primary sites including a vein thrombus and two adrenal metastases.All sites were heterogeneous and polyclonal, each tumour site containing two different aggressive subclonal populations, with differentially expressed genes implicated in distinct biological functions. These are rare primary metastatic samples prior to any medical treatment, where we showed a multiple metastatic seeding of two subclonal populations.Multiple interdependent lineages could be the source of metastatic heterogeneity in ccRCC. By sampling metastases, patients with resistance to therapies could benefit a combination of targeted therapies based on more than one aggressive clone.
ISSN:0021-9746
1472-4146
DOI:10.1136/jclinpath-2020-207326